San Diego Biomedical Research Institute

San Diego Biomedical Research Institute, a nonprofit research organization headquartered in San Diego, California, receives federal research funding as a prime grant recipient from the National Institutes of Health (NIH) and related agencies, with 90% of recent awards as a prime recipient and 10% as a sub-recipient on collaborative research grants. The institute operates exclusively in the federal grant space (no contracts or contract vehicles); all work is funded through NIH project grants and sub-awards on multi-institutional research initiatives.

The institute's capability portfolio centers on biomedical research in HIV immunology, neurodegeneration, and immunoinflammatory disease, grounded in recent peer-reviewed grant work. Representative prime awards include a $809,479 NIAID project grant (CFDA 93.855, awarded June 2026) on inducing broadly neutralizing antibodies to protect against HIV-1 infection through engineered envelope glycoprotein trimers; a $541,750 NINDS project grant (CFDA 93.853, awarded May 2026) on discovery of noncanonical autophagy modulators for Alzheimer's disease and related dementias; a $1,436,586 NHLBI project grant (CFDA 93.837, awarded September 2025) assessing CD4+ cytotoxic T lymphocytes in severe asthma response to Type 2 biologic therapies; and a $541,500 NIAID project grant (CFDA 93.855, awarded June 2025) investigating calorie restriction, body temperature reduction, and autoimmunity in lupus models. Additional work spans HIV antibody glycosylation and NK cell-mediated cytotoxicity, neuroinflammatory mechanisms in Parkinson's disease, cannabinoid effects on blood-brain barrier integrity in HIV-infected brain tissue, and hypoxia mimetics in multiple sclerosis.

Customer concentration aligns heavily with NIH institutes. The top five funding agencies account for 70% of awards by count, led by NIAID (7 awards) and NINDS (7 awards), followed by the National Institute on Drug Abuse (6 awards), the National Cancer Institute (4 awards), and the National Institute on Aging (4 awards). Combined obligated dollars across all 40 awards reach $109.4 million over the source's award date range (2007–2026). The institute has worked with 13 distinct federal agencies. In its sub-recipient role, the institute serves as a data-production collaborator on multi-scale 4D nucleome projects led by Carnegie Mellon University and participates as a research component on an HIV blood-brain barrier study led by UC San Diego, with sub-award values ranging from $462,716 to $484,305.

Activity has grown unevenly — four awards in 2022, four in 2023, seven in 2024, three in 2025, and two in 2026 — with nine awards (approximately $5.6 million in combined potential value based on the recent award magnitudes) reaching ultimate completion inside the next twenty-four months. Performance of all work occurs at the institute's San Diego, California facility. All awards are unrestricted peer-reviewed research grants; the institute does not pursue or hold federal contract vehicles, set-asides, or commercial contracting relationships.